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A. MALIGNANCY ASSOCIATED WITH PREGNANCY 
When cancer complicates pregnancy, both fetus and mother 
may be at increased risk1 , 2 . Often the obstetric mandate 
to provide a healthy neonate is jeopardized by the 
oncological need to treat the tumourl,3-5. 
Instead of an oncologist-patient duo, those involved 
include fetus, paediatrician, obstetrician and father of 
the childs. Does pregnancy negatively influence the 
survival, either through direct action or as a result of a 
delaying treatment in the interest of the neonate? 
Additional concern relates to the side-effects of 
treatment, which perta in not merely to the patient, but 
also to the baby3,5. 
Recently several general statements, regarding 
malignancy associated with pregnancy, have been made5: 
(1) Malignancy is not affected by pregnancy per se, 
but may delay diagnosis and treatment. 
(2) Pregnancy is rarely affected by the cancer 
itself. 
(3) Irradiation and 
pregnancy carry 
cytotoxic therapy during 
a significant risk of 
teratogenesis and abortion. 
Although other reports 
there remains controversy 
agree with 
regarding 
pregnancy on breast cancerl,3,6. 
these opinions 
the effect of 
2 
For the obstetrician, the problem of pregnancy-
associated cancer is an unusual one3,5,7. A Finnish 
report found an incidence of 0.07%, excluding gestational 
trophoblastic disease and including cervical 
intraepithelial neoplasia7 . In South Carolina (USA), 
amongst 37,101 pregnant women 144 malignancies (0.4 %), 
including cervical intraepithelial neoplasia, were 
reported8 . Apparently malignancy complicates less 
pregnancies than expected as demonstrated by a German 
group who found that pregnant patients had a lower 
incidence of cancer than the general female population 
(344 vs. 558.8)9. 
For the oncologist however, pregnancy associated 
cancer is relatively more common. In the series from 
Carolina, Lutz et al found a 5% pregnancy rate amongst 
their gynaecological cancer patients8 . This highlights 
the fact that pregnancy is a more prominent consideration 
to an oncologist than malignancy is to an obstetrician. 
B. INVASIVE CERVICAL CARCINOMA ASSOCIATED WITH PREGNANCY. 
Genital and breast cancer dominate published reports of 
malignancy complicated by pregnancy (Table I). 
Table I. Pregnancy-associated 
frequency. 
SITE IN 
AUTHORS 1 2 
Phelan et al Genital Breast 
(1968) 51.92 21.15 
(n = 52) 6 
Niemenen & Breast Genital 
Remen (1970) 28.24 23.53 
(n = 85) 7 
Lutz et al Genital Breast 
(1977) 42.55 24.47 
(n = 94) 8 
Haas et al Genital Breast 
(1984) 72.70 7.80 
(n = 359) 9 
3 
tumours in order of 
ORDER OF FREQUENCY ~ 0 
3 4 5 
Melanoma Thyroid Sarcoma 
5.77 5.77 3.85 
Thyroid Melanoma 
10.59 5.88 
Sarcomas Melanoma GIT 
7.45 5.32 3.19 
Lymphoma Melanoma GIT 
5.29 3.34 2.51 
More specifically, cervical cancer is the genital 
malignancy most commonly associated with pregnancy (Table 
II) and vulval, vaginal, endometrial and ovarian cancer 
are relatively rare (Table II). 
TABLE II. Reported incidence of genital malignancy 
associated with pregnancy. 
PRIMARY SITE 9-,, 0 
AUTHORS CERVIX OVARY CORPUS VULV/VAG 
Phelan 
et al 96.3 · 3. 7 - -
(N=27) 6 
Niemenen 
& Remen 85 10 - -
(N=20) 7 
Lutz et 
al 75 10 - 15 
(N=40) 8 
Haas et 
al 88.5 7.7 1. 6 1.6 
(N=261) 9 
Barber 
et al 75.8 16.3 3.3 4.8 








Reported incidences of invasive cervical cancer are 
difficult to interpret2,3,11-14. Centres contributing to 
the literature are often referral centres and may receive 
patients from several obstetric units. Furthermore, 
reports may vary with regard to exact definitions e.g some 
include postpartum patients where the post-deli very 
interval can vary between 2 and 18 months. Lastly, 
cervical intraepi thelial neoplasia i.e. preinvasi ve, is 
often reported simultaneously and figures then need 
adjustment for the incidence of invasive malignancy. 
Probably the best clue to the incidence of pregnancy-
associated cervical cancer is found in a recent review of 
7 articles15 . The aut~ors reported an average of 1 
pregnancy complicating every 34 cases of invasive cervical 
. 
cancer (2.9%). This contrasts with their finding, from 11 
5 
reports, of 1 cervical cancer complicating every 2205 
pregnancies (0.45 per 1000)15. 
Cervical cancer may be amongst the most frequent 
tumours to be affected by pregnancy (Tables I,II), but its 
occurrence is still not sufficient to enable irrefutable 
conclusions. Enigma's in pregnancy-associated cervical 
malignancy include the possible influence of pregnancy on 
prognosis and timing of deli very2, 4, 10-13, 15-29. In 
addition, and more specific to this tumour than other 
malignancies, are the problems of management during the 
second trimester and route of 
delivery2,ll,13,15,17,18,20,26,30,31. 
C. AIMS OF THIS STUDY. 
Against the background of contradictions and uncertain 
conclusions available in the literature, a study was 
undertaken to describe the experience at Groote Schuur 
Hospital of pregnancy-associated cervical cancer. From 




MATERIALS AND METHODS 
A. SOURCE OF DATA 
The names of all patients in the study group were 
retrieved from the database of the Radiotherapy Department 
at Groote Schuur Hospital (GSH) in Cape Town. 
Gynaecological oncology at this hospital is managed 
by a team of gynaecologists and radiotherapists, who 
review new cases of genital malignancy at a weekly 
Combined Assessment Clinic (CAC). 
Patients are registered with the Radiotherapy 
Department and assigned folder numbers in numerical 
sequence. This register is computerised and forms the 
above mentioned database. 
Once a patient is registered, relevant data such as 
patient characteristics, treatment and follow-up is 
recorded in a folder which is stored according to its 
number. 
GSH is a hospital located in Cape Town with the 
status of a tertiary referral hospital. Most patients 
treated at GSH live on the Cape Peninsula. However, its 
associations extend eastwards along the southern Cape 
Province and include affiliations with hospitals in Port 
Elizabeth and East London. From these satellite units 
patients with pregnancy-associated cervical cancer are 
referred to GSH according to protocol. This study thus, 
was able to accumulate a group of patients originating 
from a large area, but whose management was centralized. 
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B. DEFINITIONS 
1. Carcinoma of the cervix associated with pregnancy 
The exact definition of this association has not been 
uniform. Some studies include only patients actually 
pregnant at the time of diagnosisl 8 , 32 , 33 . Most studies 
however include patients diagnosed within the postpartum 
period4,ll,12,16,17,19,23,24,28,35-37,39. This inclusion 
is usually not motivated4,6-8,10,12-14,16,19,21-24,26-
28,30,37,40 Other studies base the inclusion on the 
likelihood that cancer in postpartum patients must have 
been present at the time of deliveryll,15,34,36,39-41. 
While it has been pointed out that most postpartum 
patients have symptoms of cancer going back to the time of 
the delivery, it has also been acknowledged that the 
definition is arbitraryll,17. 
There is a variation in the postpartum interval and 
this may reach 18 monthsl 7 . However, most reports refer 
to patients presenting within 6 to 12 months of 
delivery8,10,ll,13-16,20,22,24,26,30,38,39. 
Traditionally at Groote Schuur Hospital, the 
definition has been taken to include patients diagnosed as 
having carcinoma of the cervix within 12 months of 
pregnancy. 
2 • Invasive carcinoma of the cervix. 
At GSH, only patients with carcinoma of the cervix 
greater than or equal to stage IB ( FIGO) are registered 
with the Radiotherapy Department. Patients with stage IA 
or cervical intraepithelial neoplasia (CIN) are managed 
without referral to the CAC. As this study made use of 
8 
computerized data from the Department of Radiotherapy, it 
was decided not to include patients with CIN or stage IA 
disease. 
C. STUDY DESIGN 
Pregnancy-associated cervical cancer was studied by 
observation rather than experiment. The current study is 
primarily descriptive, but in order to analyze the 
influence of associated pregnancy on the survival of 
cervical cancer the non-concurrent cohort method was 
chosen. 
The descriptive method was used to quantify the 
extent of this complication amongst GSH cervical cancer 
patients. The cohort method enables one to determine, on a 
comparative basis, the role of associated pregnancy as a 
risk factor in cervical cancer. 
D. SELECTION OF PATIENTS 
1. Study Group 
The study period was from 1970 as the radiotherapy 
database of GSH contains patient information from that 
year onwards. In order to achieve meaningful survival 
data, provision was made for a minimum follow-up of 5 
years. Thus the study period was taken from 1970 to 1984 
inclusive, allowing a 5 year follow-up until December 
1989. 
From the cervical cancer patients registered during 
the study period, the names and folder numbers were drawn 
of patients with associated pregnancy. These compiled the 
9 
study group. Henceforth these will be referred to as 
"pregnant" patients. 
2. Control group 
A control group was compiled of cervical cancer 
patients NOT associated with pregnancy i.e. non-pregnant 
patients. Selection of the control group was arbitrary-
the patient registered immediately after a study patient 
was entered. 
3. Exclusion criteria 
Patient records were perused and the following 
exclusion criteria were applied: 
(1) Patients with stage IA carcinoma of the 
cervix, who had been erroneously 
registered. 
( 2) Patients in the pregnant group in whom 
the pregnancy-diagnosis interval exceeded 
12 months. 
(3) Patients from areas where adequate 
follow-up was not feasible. 
(4) Patients in whom cancer treatment had 
been initiated in other centres, prior to 
registration at GSH. 
E. COMPOSITION OF DATA 
Once study and control groups had been compiled, patient 
records were examined by two observers and the following 
aspects given attention: 
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1. Age 
This was calculated as the number of calendar years 
completed at diagnosis. 
2. Parity 
Where study patients were pregnant at diagnosis, 
parity equalled the number of previous pregnancies 
producing a viable infant. For postpartum patients, the 
pregnancy associated with the carcinoma was included in 
the parity. 
3. Stage 
The criteria for staging of cervical cancer has been 
set by the Oncology Committee of the Federation 
International Gynaecologie et Obstetrie (FIG0)42-44. 
4. Histology 
Records listed histology number, tumour type and 
differentiation. 
Using the histology number, an attempt was made to 
recover as many histology specimens as possible. Where 
original histological analysis was not performed in Cape 
Town, an attempt was made to obtain original histology 
specimens from other laboratories (i.e. East London and 
Port Elizabeth). The specimens thus retrieved were 
reviewed by a single pathologist (Professor A. Tiltman). 
Al though aware of the diagnosis i.e. carcinoma of the 
cervix, he was unacquainted with all other patient 
details. 
5. Time of diagnosis in relation to pregnancy 
At diagnosis study patients were either: 
a) antenatal or 
b) postpartum. 
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Note: (Control patients were "non-pregnant"). 
The method of diagnosis is important in making this 
distinction as it was often necessary to make a clinical 
diagnosis in order to manage the patient appropriately. 
Consider the patient who has never had antenatal care and 
who presents in labour. If her attendant practitioner 
suspects cervical cancer, he may be influenced to perform 
a Caesarean section. This in fact happened in areas where 
frozen section was unavailable. Thus some patients have 
been labelled antenatal even though the diagnosis was only 
confirmed histologically postpartum. 
a) Antenatal patients. With regard to antenatal 
patients, the gestational age at diagnosis was calculated. 
On occasions, this figure was difficult to assess 
accurately as, for most of the study period, 
ul trasonography was not available at Groote Schuur. It 
was necessary thus to use a combination of menstrual dates 
and clinical assessment to arrive at an estimation of 
gestational age. 
b) Postpartum patients. The interval between 
delivery and assessment at CAC was recorded. It was 
assumed that the date of assessment at the CAC 
represented the onset of active treatment of the patient. 
In some cases, the exact date of delivery was not 
mentioned in patient records and thus the time interval 
was recorded only as a certain number of months. An 
estimation was made in weeks by assuming 30 days to each 
month. 
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6. · Delivery of study patients 
Details concerning deli very were obtained from all 
study patients, whether postpartum or antenatal. 
7. Treatment 
Records for each patient were reviewed to see if 
surgery, radiotherapy, a combination thereof or no 
treatment had been used. Details of treatment were 
re·corded. 
8. Survival 
For each patient, the interval between registration 
with the CAC and exit from the study was determined. Exit 
from the study was the date of last recorded entry into a 
patient's folder. 
In order to construct survival curves, it was 
necessary to determine each patient's status at exit from 
the study. Thus patients could be: 
a) alive with no evidence of disease; 
b) alive with disease; 
c) dead from cervical cancer; 
d) dead from unrelated causes; 
e) lost to follow-up. 
F. ANALYSIS OF DATA 
1. Study and control patients were compared for: 
a) Age; 
b) Parity; 
c) Stage distribution 




2. Study patients were analyzed for the effect on 
survival of: 
a) Stage distribution; 
b) Mode of delivery; 
c) Relationship to pregnancy; 
d) Treatment modality. 
G. STATISTICAL CONSIDERATIONS 
The Institute of Biostatistics at the Medical Research 
Council (MRC) was consulted about data analysis. 
Study and control groups were compared for age, 
parity, stage distribution and histology, using the chi-
square test. 
Survival data was analysed by constructing survival 
curves and the logrank test was used to assess for 
significant differences. 
Where survival was thought to be influenced by co-
variables, Cox's Proportional Hazards Regression methods 




A. PROPORTIONAL OCCURRENCE 
In the period 1970 to 1984, 62 patients were treated at 
Groote Schuur Hospital for cervical cancer associated with 
pregnancy. In the same period, 1303 patients were treated 
for cervical cancer at this institution. Thus the 
proportion of cervical cancer patients with associated 
pregnancy was 4.76%. A negative trend was found during the 
study period (Table III). 
TABLE III. Proportion of cervical cancer patients with 
associated pregancy. 
1970-74 1975-79 1980-84 TOTAL 
ca . ex. associ-
ated with 
pregnancy 25 20 17 62 
Total ca.ex. 
population 
treated at GSH 349 388 566 1303 
Proportion of 
pregnancy assoc-
iated ca.ex. 7.16% 5.15% 3.60% 4.76% 
Proportion 1970-74 vs 1975-79 P<.4 (ch.sq) 
1975-79 vs 1980-84 P<.2 (ch.sq) 
1970-74 vs 1980-84 P<.006 (ch.sq) 
The proportion of pregnant patients with cervical 
cancer during these years was not calculated because GSH 




The mean age of the patients in the study group was 32.5 
years (range 19-43 years). Patients in the control group 
averaged 4 9 . 6 years ( range 27-91 years) and were 
significantly older than study patients (Wilcoxon 2-sample 
test P<0.001) 
C. PARITY 
Mean parity was almost identical in study and control 
patients (4.97 and 4.98 respectively) with ranges which 
were also similar (2 - 12 and O - 15 respectively). 
D. STAGE DISTRIBUTION 
Analysis of stage distribution revealed that there were 
significantly more pregnant patients with stage IB 
disease. Alternately more patients in the control group 
presented with stage IIIB carcinoma of the cervix (Table 
IV). 
TABLE IV. Stage distribution. 
STAGE STUDY CONTROL SIGNIFICANCE 
n=62 n=62 P-value 
IB 19 8 <.03 
IIA 9 6 .58 
IIB 17 11 .28 
IIIA -- 1 --
IIIB 15 29 <.009 
IV 2 7 --
TOTAL 62 62 
These results were rationalized further into early 
stage disease (ESD) i.e. stage IB and IIA, and late stage 
16 
disease (LSD) i.e. stage IIB to IV. A significant 
difference could again be demonstrated using this 
rationalization (Table V). 






ESD = Early Stage Disease 








Slides were recovered for 30 study patients and 26 
controls ( Table VI) . Analysis of this data revealed no 
significant differences. 
TABLE VI. Distribution of histological types. 
HISTOLOGY STUDY CONTROL 
n=30 n=26 
( % ) ( % ) 
Squamous ca. 23 (76.7) 16 ( 61. 5) 
Adenoca. 1 ( 3 . 3 ) 4 (15.4) 
Ade no squamous ca. 4 (13.3) 4 (15.4) 
Glassy cell ca. 2 ( 6 . 7 ) 0 ( 0) 
Undifferentiated ca. 0 ( 0 ) 2 ( 7 . 3 ) 
Total recovered 30 (100) 26 (100) 
F. TIME OF DIAGNOSIS IN RELATION TO PREGNANCY 
Thirty two patients (51.6%) in the study group were 
pregnant at presentation while the remaining 30 ( 48. 4%) 
were postpartum when diagnosed as having pregnancy-
. 17 
associated cervical cancer. Of the former, 3 patients 
(9.3%) were treated during the first trimester, 11 (34.4%) 
in the second and 18 (56.3%) in the third trimester. 
Amongst the postpartum patients, 18 patients ( 60%) 
were treated in the 6 months following delivery and 12 
(40%) thereafter. 
Analysis of the time of diagnosis in relation to 
delivery, when defined as either an abortion (early or 
late) or third-trimester delivery, was carried out. This 
revealed that 31 patients (50%) were diagnosed either in 
the last 12 of pregnancy or in 12 weeks following delivery 
(Figure 1). 
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ANTENATAL POSTPARTUM 
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G. EFFECT OF TIME OF DIAGNOSIS IN RELATION TO PREGNANCY, ON 
STAGE DISTRIBUTION 
Gestational age and postpartum interval at diagnosis 
appeared to influence stage distribution insofar as more 
advanced disease was found later in pregnancy and as the 
postpartum interval increased (Table VII). However, the 
small number involved negated meaningful statistical 
analysis. 




1st & 2nd 12 2 
3rd 8 10 
6 mths postpartum 8 10 
6-12 mths postpartum 0 12 
TOTAL 28 34 
Patients diagnosed postpartum had significantly 
(ch. sq. P<O. 01) more advanced disease than those in the 
antenatal group (Table VIII). 




Pregnant 20 12 
Postpartum 8 22 
TOTAL 28 34 
ch.sq P<0.01 
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H. METHOD OF DELIVERY 
In the study group, 23 (37.1%) of 62 patients delivered 
vaginally. This included 3 patients who aborted and 1 
patient who was given radiotherapy prior to evacuation of 
her uterus. This last patient has been excluded from 
further analysis of the influence of mode of delivery on 
survival. 
Thirty nine patients (62.9%) were delivered 
abdominally. This included 27 patients who had Caesarean 
section, 9 who had a hysterotomy and 1 patient who had a 
radical hysterectomy with fetus-in-situ. Two patients in 
this abdominal group were excluded from further analysis 
of survival. One patient defaulted before initiation of 
therapy after abdominal delivery (Caesarean section). The 
second patient underwent a hysterotomy within 4 days of 
the first radium application. At laparotomy a uterine 
perforation was diagnosed which presumably had occured 
during the radium application. This patient died 
immediatly afterwards of fulminating sepsis. 
Therefore 59 patients were suitable for analysis of 
stage distribution and survival. 
Evaluation of stage distribution vs mode of delivery 
showed that patients who delivered vaginally had a trend 
towards late stage disease but did not show a significant 
difference (ch.sq. P=0.08) (Table IX). 
20 
TABLE IX. Extent of disease vs mode of delivery 
STAGE VAGINAL ABDOMINAL 
(n = 22) (n =37) 
IB 3 15 
IIA 3 5 
IIB 9 7 
III 6 9 
IV 1 1 
ESD 6 20 
LSD 16 17 
ch.sq. P=0.08 
I. THERAPY 
Analysis of the treatment amongst the 124 patients showed 
that primary radiotherapy was the commonest form of 
treatment. For both groups there was no significant 
difference in the frequency of its application. For the 
other modalities small numbers precluded meaningful 
statistical analysis (Tables X & XI). 
TABLE X: Summary of therapy 
Pregnant Non-pregnant 
n=62 n=62 
Primary XRT 42 53 
Primary surgery 9 3* 
Primary surgery+ 2 
0 
XRT 8 3 
Primary XRT and 20 
surgery 2 0 
No treatment 1 3 
*1 patient received chemotherapy post-operatively 
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TABLE XI: Therapy according to stage of disease 
ESD LSD 
PREGNANT NON-PREGNANT PREGNANT NON-PREGNANT 
1°surgery alone 9 3* 0 
l
0
XRT alone 11 8 32 
l 0 surgery+2°XRT 6 3 0 
l 0 XRT+2°surgery 1 0 2 
No treatment 1 0 0 
Total 28 14 34 








Primary surgery i.e. radical hysterectomy and pelvic 
lymphadenectomy, was always an attempt at definitive, 
curative therapy. 
adequate. Of these, 
In 11 patients this was deemed t~ be 
9 patients were pregnant, while 2 
patient belonged in the control group (Table XI). 
In six study patients, surgery was performed but 
adjuvant treatment was required. In 1 patient surgery was 
abandonded after frozen section of an enlarged common 
iliac node showed metastatic disease. In 4 patients 
adjuvant radiotherapy was thought necessary because of 
risk factors (incomplete resection in 3 patients and 
pelvic nodal disease in the surgical specimen of 1 
patient). Thus 40% of patients in whom radical surgery 
was attempted required adjunctive therapy. The last 
patient had radiotherapy after surgery because histology 
of a simple hysterectomy specimen, performed for suspected 
stage IA disease, revealed frank invasion. 
In the control group, 3 patients required 
postoperative radiotherapy. Two of these patients had 
nodal metastases at staging laparotomy. The third had 
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unsuspected invasive cervical cancer found after a simple 
hysterectomy. 
Two pregnant patients received radiotherapy followed 
by surgery. One patient had stage IIIB disease. 
Radiotherapy was given and this was followed by a salvage 
hysterectomy because of excellent tumour regression. The 
second patient presented in labour and was diagnosed as 
having cervical cancer. Post-delivery she was staged as 









disease was found. 
she defaulted from 
reappeared after four 






Summarizing these results it appears that in 15 
pregnant patients and in 6 non-pregnant patients radical 
surgery was attempted. The results of this therapeutic 
approach were thought to be sufficient in 9 pregnant 
patients (9/15=60%) and in 2 non-pregnant patients 
( 2/6=33%). A comparison is not possible because of the 
small numbers involved. 
2. Radiotherapy 
Conventional brachytherapy and/or teletherapy was 
employed where suitable. The former was by way of radium 
insertions and the latter using a cobalt source. Amongst 
the group associated with pregnancy there were 3 4 cases 
who had late stage disease. Of these, 32 patients (94.1%) 
received radiotherapy only, while the remaining 2 patients 
(5.9%) had radiotherapy followed by surgery. These 2 
patients were described earlier. 
patients had late stage disease. 
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Forty-eight control 
Fo~ty four of these 
patients (91.7%) had primary radiotherapy. In 3 patients 
(6.3%) the disease was considered too advanced to warrant 
any form of treatment. The last patient was administered 
adjuvant radiotherapy after histology of a hysterectomy 
specimen confirmed a previously unsuspected cervical 
carcinoma. 
Of 28 study patients with early stage disease 11 
( 39. 3%) were treated with primary radiotherapy. Amongst 
controls, eight ( 57 .1%) with early stage disease ( n=l4) 
were similarly treated. Statistical analysis revealed no 
significant difference (P=0.9) in the overall use of 
primary radiotherapy for early stage disease. 
The use of primary radiotherapy in early stage 
disease was investigated further · and it was found that 
before 1978, all these patients (study and control 
included; n=20) were treated with primary radiotherapy. 
Thereafter, with the exception of two patients (1 in each 
group) an attempt was always made to treat patients with 
early stage disease (n=22) with radical surgery. 
J. SURVIVAL 
1. Overall survival 
The overall survival for 124 patients analysed is 
depicted numerically in Table XII. 
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TABLE XII. Overall survival 
. 
Survival Pregnant Non- p 
n=62(%) pregnant value 
n=62(%) ch.sq. 
Survival at 5 yrs 23(37.1) 18(29) .2 
Lost to follow-up 
within 5 yrs. 15(24.2) 6(9.7) .06 
Died due to disease 
within 5 yrs 20(32.3) 36(58.1) .007 
- from 0-2 yrs 15(24.2) 29(46.8) .01 
- from 2-5 yrs 5(8.1) 7(11.3) .7 
Died due to treatment 2(3.2) 1(1.6) NA 
Died from unrelated 
causes 2(3.2) 1(1.6) NA 
NA: Not applicable because of small numbers 
Table XII depicts survival in two ways: 5 years 
survival and death rate. The apparent contradiction 
between these two measurements of survival can be 
explained by the difference in loss to follow up which 
existed between study and control groups (P=0.06). A third 
method of assessing survival i.e. the survival curve, was 
employed ( Figure 2). The logrank test comparing the two 
groups showed a significant difference with a better 
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2. Survival vs stage 
70 80 90 100 
As there was a significant difference in stage 
distribution between the two groups, stage was 
investigated for its effect on survival and was shown to 
affect survival (Wilcoxon P-value = 0.004). In the light 
of this result survival was stratified for stage (ESD, 
LSD). Life tables were thus constructed to analyse the 
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The logrank test was applied to this data and showed 
no difference in survival between the pregnant and non-
pregnant patients when stratified for stage. For patients 
with ESD, the logrank P-value was 0.07, while for patients 
with LSD, the logrank P-value equalled 0.61. 
3 • Survival vs therapy 
Survival was assessed for any difference according to 
treatment modality. This comparison was irrelevant in LSD 
as radiotherapy was uniformly applied to this stage 
grouping. The survival of ESD for the study and. control 
groups showed no difference (Willcoxon:P=.19) when 
stratified for therapy i.e. radiotherapy or surgery. 
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4. survival vs mode of delivery <: 
Patients with associated pregnancy were analysed for 
the influence of mode of delivery on survival. Of patients 
suitable for this analysis 22 patients delivered vaginally 
and 37 delivered abdominally (See section H of this 
chapter). Overall survival for these two groups showed no 
significant difference (logrank;P=O,l) and is represented 
in Figure 4. 
FIGURE 4. Survival according to mode of delivery 
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After stratifying for stage the method of deli very 
was again found to have no significant effect (Wilcoxon; P 









FIGURE 5. survival according to mode of delivery 
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5. Survival vs relationship to pregnancy 
70 80 
The survival for patients diagnosed antenatally and 
postnatally was evaluated and demonstrated no significant 
difference (logrank;P=0,4) for these two groups of 
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Because of the small numbers invol'led it was not 
feasable to stratify for stage. 
6. Multivariate analysis of survival . 
A forward step-wise sequence analysis of chi-squares 
for Wilcoxon showed that stage, mode of delivery and time 
of diagnosis in relation to pregnancy had the greatest 
influence on survival. A Proportional Hazards General 
Linear Model was then used to determine the direction of 
this influence and the following result were found: 
( l) Stage had a significant influence on survival 
(P<0.0001). 
( 2) The interval between conception and diagnosis 
significantly (P<0.03) affected survival; in 
other words the further (in time) from 














(3) The mode of delivery influenced survival to a 
certain degree (P=0.08) i.e. in this study the 
prognosis of patients who delivered vaginally 
seemed to be worse than those who were 
delivered abdominally. 
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Based on the results of the multivariate analysis, 1, 
3 and 5-year survival probability curves were constructed 
(Figure 7a,b,c). 
FIGURE 7a. Survival probabilities at 1 year. 
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FIGURE 7c. Survival probabilities at 5 years 
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These curves confirm that the probability of survival 
increases in early stage disease, with progressive 
interval between conception and diagnosis, and in patients 
delivered abdominally. This probability also plateaus 




This study on pregnancy-associated cervical carcinoma was 
undertaken to determine the extent of this problem at 
Groote Schuur Hospital (GSH) and an attempt was made to 
clarify the uncertainties regarding management and 
survival. In order to do this a number of parameters 
required investigation. 
A. STUDY SIZE AND PROPORTIONAL OCCURRENCE. 
This study compiled a report of 62 patients with cervical 
carcinoma, in whom pregnancy was associated. This 
represents the GSH experience between 1970 and 1984. 
In a review on this subject, Shingleton and Orr 
listed 24 reports in which patient numbers range from 12 
to 327 (median 41; mean 61) 2 . Thus the current study, in 
terms of patient numbers, is comparable to existing 
studies. 
In the current study the proportional occurrence of 
pregnancy associated cervical carcinoma was 4,76 %. 
Comparing this figure with existing literature requires 
caution as cervical dysplasia is frequently reported with 
invasive carcinoma and the postpartum period allowed also 
variesB-21,23,24,26,27,32,34-36,38-41. These factors will 
have an incremental influence on proportional occurrence. 
Only seven studies refer exclusively to invasive cervical 
carcinoma and a postpartum interval of 12 
monthsll,13,1 6 ,22, 24,30,39. In five of these studies the 
average number of patients with pregnancy associated 
34 
invasive carcinoma was 170 (range 30 to 327) and the 
average occurrence 3 .18% ( range 1, 9 to 3, 9%). The two 
remaining studies did not allow these calculations11, 16. 
As the number of patients in the current study is well 
within the range of these comparable studies it is 
justified to conclude that the proportional occurrence of 
pregnancy associated cervical carcinoma at GSH is higher 
than elsewhere. 
B. AGE 
The average age of the patients with pregnancy associated 
cervical carcinoma in the current study was 32.48 (range 
19 - 43). This is similar to previously reported studies 
in which mean age ranged from 31 to 36.5 years 8 ,11-
14,17,18,22,24,26,30,34,35,37,38. 
In previous reports the difference in mean age 
between pregnant and non-pregnant patients varied between 
15 and 18 yearsll, 24 ,30,34,35. The pregnant patients in 
the current study were 17,15 years younger than non-
pregnant patients, which confirms a similarity to those 
elsewhere in the world in respect of age. 
Although the prognostic 
survival of cervical carcinoma 
GSH it has been shown not to 
influence of age on the 
is controversia145,46 at 
I 
influence outcome4 7 . Thus 
despite a mean age difference of 17.15 years between study 
and control groups, an analysis of the influence of 
pregnancy, as a single prognosticator, was justified. 
C. PARITY 
The parity of the pregnant patients in this study averaged 
4,97 and was comparable to that of the non-pregnant 
35 
patients (average 4,98). Thus an association of 
multiparity and cervical carcinoma was demonstrated. In a 
review by Hacker et al, the average parity of pregnant 
cervical carcinoma patients was 4.515 . This emphasizes 
that the parity of the pregnant patients in the present 
study was similar to that reported elsewhere. 
D. STAGE DISTRIBUTION 
The entire subject of pregnancy associated cervical 
carcinoma is handicapped by small numbers which hinder 
statistical analysis2, 1 2 , 1 5- 21 . This becomes evident if 
stage distribution in the current study is analyzed (Table 
IV). Therefore 28 patients were categorized as having 
early stage disease (ESD) including stages IB and IIA, and 
34 patients as late stage disease (LSD) which comprised 
stages IIB, III and IV. This sub-classification of disease 
progression has been utilized elsewhere to make analysis 
more meaningful 48 , 49 . Such a sub-cl a ssif ication has 
practical implications in that ESD patients are candidates 
for radical surgery whereas LSD patients are traditionally 
treated with radiotherapyl0, 24 , 28 , 36 ,50. This approach to 
treatment is also applied at GSH. 
Between 1970 and 1984 nearly half (45%) of the 
patients with pregnancy associated cervical carcinoma at 
GSH had ESD. Comparing this figure with that in other 
studies proves to be difficult for a number of reasons. 
(1) Only 7 studies define the staging 
classification utilized8,12,13,18,26,27,41. 
( 2) Three of these ref erred to the League of 
Nations' staging13 , 27 ,41, while the 
remainder used the FIGO staging8,12,18,26. 
(3) FIGO staging criteria were compiled in 1950, 
modified in 1961,1970, 1976 and most 
recently in 198842-44,51, 52 . These 
modifications are particularly relevant 
with regard to the distinction between 
microinvasive and frankly invasive disease. 





stages IA and 
The current study 
patients with IA 
(5) Lastly, in only 6 studies were patients with 
stage II disease divided into "A" and 
"B"7,8,18,19,33,36. This meant that the 
ESD/LSD system could not be universally 
applied for reasons of comparison. Although 
the staging system in 4 of these reports 
was not specifically mentioned it can 
reasonably be assumed that the FIGO 
classification was operative. 
.3 6 
In order to overcome these variations in reporting 
and to achieve a comparison regarding stage distribution 
in the GSH study, the 6 studies mentioned under (5) were 
reviewed7 ,8,18,19,J3,36 (Table XIII). In these 6 reports 
microinvasi ve disease was distinguished from IB disease, 
although admittedly, definitions of microinvasion varied. 
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TABLE XIII: Comparative stage distribution in carcinoma 
of the cervix associated with pregnancy. 
ESD 
Niemenin 7 11 
Lutz 8 10 
O'Leary18 9 





ESD: Early Stage Disease 
LSD: Late Stage Disease 










that at GSH, ESD was 
considerably less common than elsewhere. Further analysis 
of the 6 reports however showed that 3 of these reports 
included no postpartum patients7,18,33; the fourth 
included patients within two months of delivery36, the 
fifth within three months of deliveryl9 and the last 
report included a postpartum period of 6 months8. These 
observations are to a certain degree relevant as 
postpartum interval has been reported to influence stage 
distributionl5. Considering only patients 1n the current 
study who were pregnant or within three months of 
delivery, 60% had ESD (27/45). This ESD rate is still 
lower than reported elsewhere (Table XIII). 
In the review by Hacker et al, the accumulated 
frequency of pregnant patients with stage IB disease, 
which included varied postpartum interval, was 42% 
38 
(637/1517) 15 , whilst amongst the GSH patients the 
equivalent figure was only 30,6% (19/62). 
These comparisons point to the occurrence amongst GSH 
patients, of more advanced disease than elsewhere. 
In the current study the occurrence of ESD in 
pregnant (45,1% ESD) and non-pregnant patients (22,6% ESD) 
was significantly different (ch.sq. P<O. 02) . This 
difference may result from the greater exposure of 
pregnant patients to heal th care e.g. antenatal visits, 
vaginal examination and cervical cytologyl4, 34, 38, 40, 53. 
Additionally, more advanced disease might prevent 
conception39. Lastly, this difference may merely be a 
manifestation of the age difference between study and 
control groups. Jennings in his recent analysis of age 
related cervical carcinoma at GSH found almost identical 
difference in stage distribution between a younger (mean 
age 29.9 years) and an older group (mean age 53.4 years) 47 
(Table XIV). 
TABLE XIV. Stage distribution GSH pregnant vs. GSH young 
patients 
ESD(%) LSD(%) 
GSH pregnant 45.2 54.8 
GSH young 47 48.1 51. 9 
The increased proportion of ESD in the pregnant group 
signals a positive influence on the survival of these 
patients. Unfortunately, the ESD/LSD system cannot be used 
to compare the occurrence of ESD in the current study with 
that reported elsewhere. Control patients in other reports 
are not described in sufficient detail-not even the 
39 
reports in Table XIII help in this comparison. Hacker et 
al studied the occurrence of stage IB disease in pregnant 
patients and compared this to the occurrence of IB disease 
reported by FIGolS,43. Table XV illustrates these figures 
alongside those from the GSH study and it seems as though 
our patients, whether pregnant or not, presented with more 
advanced disease than elsewhere. However, the difference 
between our pregnant and non-pregnant patients (30,6% vs. 
12.9%) seems to be comparable to elsewhere (42 % vs. 26,8 %) 
(Table XV). 
TABLE XV. Occurrence of stage IB disease in 
pregnant and non-pregnant patients. 
GSH 
Hacker e t a115. 







In summary, GSH patients with cervical carcinoma , 
whether or not associated with pregnancy, present with 
later disease. This may be a reflection of a "Third World" 
situation 
E. HISTOLOGY 
Tumour type is thought to be important as a prognosticator 
for cervical carcinoma 54 . Adenocarcinoma and adeno-
squamous carcinoma have been reported to carry a greater 
risk54 . The low yield of specimens in the cur rent study 
negated any meaningful statistical analysis. 
The most common tumour type occuring in pregnancy-
associated cervical carcinoma is squamous carcinomal5. 
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Glassy cell carcinoma of the cervix has been reported to 
occur more frequently in association with pregnancy53 ,55. 
This tumour type is the least differentiated form of 
adeno-squamous carcinoma of the cervix and carries a poor 
prognosis. 
F. TIME OF DIAGNOSIS IN RELATION TO PREGNANCY. 
Various reports have demonstrated the relevance of the 
time of diagnosis in relation to pregnancy. In most 
studies it appears that patients who are diagnosed 
antenatally have a better survival than their postpartum 
counterparts13,15-17,22,30,39,40, 56 . Moreover, the earlier 
during pregnancy that a diagnosis is made, the better the 
prognosis8,13,15,16,22,27,34,38,41. Contradictory reports 
to the latter statement do however exist1 7 ,1 8 . 
In the current study as many patients were diagnosed 
antenatally (32/62; 51.6 %) as postpartum (30/62; 48.4 %) 
whereas in comparable studies (i.e. where a postpartum 
interval of 12 months was taken into consideration) it was 
shown that more patients were diagnosed 
postpartum lo, 11, 13, 22, 24, 30, 39 . In other series, no more 
than 50 % of the patients were diagnosed during the 
antenatal period (Table XVI). 
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TABLE XVI. Distribution of patients in relation to 
time of diagnosis. 
Time of diagnosis 
Antenatal(%) Postnatal(%) 
Barber et a1lO 10/32(31.3) 22/32 (68.8) 
Waldrop et a1ll 50/182 (27.5) 132/182 (72.5) 
Sablinska et a122 63/327 (19,3%) 264/327 (80.7) 
Gustafsson et a1 13 82/239 (34,3%) 157/239 (65.7) 
Mikuta 24 14/30 (46,7%) 16/30 (53.3) 
van Praagh et a130 41/84 (48,8%) 43/84 ( 51. 2) 
Bosch et a1 39 26/66 (39.4) 40/66 (60.6) 
GSH 32/62 (51,6%) 30/62 (48.4) 
Not many factors have been identified which 
contribute to a more frequent postpartum diagnosis. There 
is however some concern about delayed diagnosis which 
results from the reluctance of practitioners to adequately 
examine the cervix of pregnant patients with suspicious 
symptoms such as vaginal bleeding or discharge 
10, 13, 22, 30, 38 Routine vaginal examination and cervical 
cytology, as part of antenatal care, will reduce the 
occurrence of postpartum diagnosisll,16,18,20,22,39,57, 
It is surprising that in the current study, time of 
diagnosis was equally distributed between antenatal and 
postpartum patients. In a so-called "Third World" 
environment, with its supposed sub-optimal antenatal care 
and poor patient compliance, one would expect a greater 
proportion of patients diagnosed postnatally. An easy 
explanation for this finding could not be found. 
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G. THE EFFECT OF THE TIME OF DIAGNOSIS, IN RELATION TO 
PREGNANCY, ON STAGE DISTRIBUTION. 
Survival in patients with pregnancy-associated cervical 
carcinoma may be affected by the time of diagnosis as a 
result of tumour stage 8 , 14 - 16 , 27 , 34 , 36 , 38 , 39 . In previous 
studies more advanced disease has been found in later 
pregnancy and in the postpartum 
period2,ll,13,14,22,30,38,39,58. In the current study 
62 . 5% of the antenatal patients presented with ESD, while 
only 39.2% (ch.sq. P<0.01) of the postnatal patients were 
found to present with ESD. 
Comparing the findings of this study with those of 
Sablinska 
antenatal 
et a122 I it appeared that, at GSH, fewer 
and postnatal patients presented with IB 
disease, but that the differences between these groups of 





stage IB disease in relation to time of 
diagnosis 
Stage IB disease 
Antenatal(%) Postnatal(%) 
Frequency 
et a1 22 43/63(68.3) 71/264(28.9) 
15/32(46.9) 4/30 (13.3) 
Several factors, alone or in combination, have been 
suggested to explain the propensity for more advanced 
disease if a diagnosis is made later in pregnancy or 
postpartum. Firstly, the already mentioned reluctance to 
examine pregnant patients with relevant symptoms might 
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explain this phenomenon10 , 13 , 22, 30 , 38 . Secondly, 
postpartum bleeding due to tumour may be misinterpreted as 
physiologica1 39. Thirdly, postpartum disease might have 
been present for longer and thus be more advanced30, 38. 




likelihood · of advanced carcinoma in early 
Fifthly, laxity of pel vie ligaments due to 




H. METHOD OF DELIVERY 
Finally, 
may be a 
advanced disease 
reflection of poor 
in the 
patient 
The relevance of method of delivery has been discussed in 
previous studies because of its possible impact on long-
term prognosis2,4,ll,13,15-18,20,23,26,30,34,38,59-61. 
Moreover, fears have been expressed at the possibility of 
dystocia, sepsis, haemorrhage and dissemination of tumour 
cells caused by dilatation of an untreated malignant 
cervix4' 10' 12' 15' 16 '23' 34' 38' 39 '59. Concern has not been 
voiced, particularly regarding the first and second 
trimesters, if radiotherapy is given prior to deli very3-
5, ll-13, 15, 16,30,37-39, 41 
A 37.3% vaginal delivery rate in this series is much 
lower than reported elsewhere. Shingleton and Orr in a 
review list 12 reports and found that 77.6% (436/562) of 
the patients had delivered vaginally (range:44.4 to 
93.3%) 2 . However, accurate comparison is 






deliveries earlier than the 3rd trimester, and the 
postpartum interval in their review was not uniform. 
Three previous reports were found, which referred to 
a postpartum interval of 12 months, and included all 
stages and gestational ages (Table XVIII). 




Barber et allO 28/32 87.5 
Mikuta 24 16/28 57.1 
Bosch et a139 34/66 51. 5 
GSH 22/59 37.3 
An explanation for the relatively low vaginal 
delivery rate at GSH might be that the majority of the 
patients in the current study presented with late, and 
therefore obvious, disease. Obvious disease would have 
favoured an abdominal delivery. Another explanation can be 
sought in the fact that in the current study, with the 
exception of one patient, all patients who delivered 
vaginally, were not pretreated with radiotherapy, while in 
previous studies a larger, but unknown number of patients, 
who delivered vaginally were pretreated and had a 
deliberate vaginal delivery. 
I. STAGE DISTRIBUTION VS METHOD OF DELIVERY. 
In the current study only 27. 3% ( 6/22) of patients who 
delivered vaginally had ESD. On the other hand, the 
proportion of ESD amongst patients delivered abdominally 
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was 54.1% (20/37). This tendency has been found in one 
previous study60 and obviously has an impact on survival 
for these 2 groups. 
Other studies stratify for stage according to method 
of delivery, but provide 






Further analysis of the 22 patients who delivered 
vaginally, revealed, that with the exception of one 
patient, diagnosis was always postpartum (95.5%). 
Conversely, only 9 patients out of 37 (24.3%) who 
delivered abdominally, were diagnosed in the postpartum 
period. It has already been mentioned that the ESD rate in 
the "vaginal" group was only 27 .3 %. It is only appropriate 
to analyze the ESD rate in the postpartum "abdominal 
group" and amongst these 9 patients the ESD rate was 
similarly poor (22.2%; 2/9). Therefore it is justifiable 
to speculate that it is more likely to be the postpartum 
diagnosis which influences stage distribution, than the 
method of delivery. 
J. THERAPY. 
The treatment of carcinoma of the cervix in a pregnant 
patient has been discussed at length in the literature. It 
would seem that such a treatment should be individualized 
rather than part of a rigid protoco118,38. 
Surgery and radiotherapy were used at Groote Schuur 
Hospital during the study period. 
Radiotherapy was nearly always (94.1%; 32/34) used in 
"pregnant" patients who presented with LSD, whilst surgery 
,· 
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was reserved for palliation or salvage hysterectomy (5.9%; 
. 
2/34). This approach did not differ from that in the non-
pregnant group with LSD, where radiotherapy was used in 
91. 7% of the patients ( 44/48) and in 4 patients ( 8. 3%) 
palliative surgery was performed. 
Amongst II pregnant" ESD patients, radiotherapy alone 
was used in 39. 3% of the patients ( 11/28) and surgery 
alone in 32.1% (9/28). Surgery and radiotherapy in 
combination were used in 25% of the patients (7/28), while 
the remaining patient with ESD defaulted and did not 
undergo any form of treatment. In comparison, 14.3% (2/14) 
of the patients in the non-pregnant group with ESD had 
surgery alone, 57.2% (8/14) received radiotherapy and 
28.6% (4/14) had combination treatment. 
These results demonstrate that patients with cervical 
carcinoma, whether associated with or not associated with 
pregnancy, were treated similarly and could therefore be 
compared for survival. 
Previous reports shared a similar experience and 
advocated a stage-related approach to cervical carcinoma, 
irrespective of whether or not associated pregnancy was 
present8,ll,16,34,38,40. 
Many authors note that tissue planes during surgery 
in a pregnant patient, are more pronounced because of 
oedemal0,12,18,27,34,36,39,40,62,64. Nevertheless, there 
are maternal complications specifically related to the 
treatment of pregnancy-associated cervical carcinoma, such 
as increased intraoperative bleeding, prolonged operating 
time and an increased risk for radiotherapy/surgery 
induced fistulae2,15,16,18-20,33. 
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There are also fetal risk factors, such as 
teratogenesis after radiotherapy4, 10, 38 and the sequelae 
of prematurity which is surgically induced12 . Although 
controversial, there may a case for delaying treatment in 
an attempt to achieve viability of the fetus 3-
5,8,10,12,14-17,19,25,26,34-36,39-41,57. It is generally 
accepted that immediate treatment should be instituted in 
the first half of pregnancy4 , 1 7 . Thereafter a maximum 
delay of four to six weeks has been suggested2,15. 
However, in exceptional circumstances this delay can be 
extended17 , 25 , 26 . 
In the first trimester radiotherapy usually results 
in a timeous abortion3,4,12,l 5 , 17 , 34 , 40 , 41 . This effect is 
less predictable in the second trimester and the resultant 
delay has led to reports of the deli very of viable, but 
badly damaged fetuses3,12,17,27, 31,3 4 , 40 . A hysterotomy in 
this trimester can obviate this 
problem8,11,12,14,15,26,31,34,39,40. 
The route of delivery as part of the treatment in the 
third trimester, is of particular relevance. Although the 
so-called "vaginal route" is associated with more advanced 
disease, in this study it has been attributed to 
postpartum diagnosis rather than the dissemination of 
tumour cells during cervical dilation. Nevertheless enough 
theoretical objections exist to justify avoiding a vaginal 
delivery if possible4,6,8,10,14-16,18,23,34,38-41. 
Primary radiotherapy was used very frequently (45.2 %) 
for treating ESD in the GSH patients. Analysis shows that 
radiotherapy was uniformly applied to both ESD and LSD 
before 1978. After 1978 all except one patient in each of 
-48 
the pregnant and non-pregnant groups, were treated for ESD 
with primary surgery. This distinct shift from 
radiotherapy to surgery can be attributed to the 
appointment in 1978 of a suitably competent gynaecological 
oncologist. 
K. SURVIVAL 
The ultimate aim of this study was to investigate the 
effect of associated pregnancy on the survival of patients 
with cervical carcinoma. Although there is some 
controversy, most authors found little influence of the 
pregnancy on survival and outcomell-14,16-
18,21,26,27,30,34-36,39-41 
In order to draw conlusions of this nature, previous 
authors have used for comparison, data drawn from either 
their cervical cancer population in toto, or their entire 
non-pregnant cervical cancer population or a population of 
non-pregnant cervical cancer patients of a similar 
age13,14,16,17,19,21,26,28,32-34,38,60. In the current 
study, for reasons of practicality and validity, a 
randomly selected sample of non-pregnant patients with 
cervical carcinoma was used. This approach has been 
utilized before to assess the influence of age on 
survival, in patients with cervical carcinoma45 ,47. 
Incomplete follow-up, inherent to a qualitative 
assessment of survival in the "Third World" situation, 
necessitated the construction of survival curves in this 
study. This method to assess survival has previously been 
well described63. 
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A comparison of survival data with previous reports, 
is fraught with difficulties for a number of reasons: 
( 1) Survival data in the literature is, with very 
few exceptions, expressed as 5-year survival 
rates and therefore cannot be compared to the 
findings in the current study. 




was analyzed according to the 
comparison could only be 
6 reports (Table XIII). 
i.e. less than 5 years, in 
contemplated with 
Inadequate follow-up 
these reports unfortunately negated any meaningful 
comparison. 
(3) Furthermore, none of the 6 reports mentioned in 
Table XIII contain any data on a control group. 
1 . Overall survival 
The overall survival in the study group at 5 years 
was 60%, whilst that of the control group was 35% (Figure 
2). The difference between these survival curves was 
significant (logrank; P 0.03) and may have resulted from 
the disparity in the stage distribution of these 2 groups 
(Table V). 
Figure 7 shows that after 36 months, there is a 
tendency for survival to plateau. This phenomenon has 
often been mentioned and seems to occur irrespective of 
associated pregnancyl4,28,47. 
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2 . Survival according to stage. 
In this study, stage as a single variable, was the 
most powerful factor to influence survival when determined 
by both univariate (Wilcoxon; P=0.004) and multivariate 
analysis (Proportional Hazards General Linear Model 
P=0 . 0001). Because of this finding any comparison of 
survival must be stratified for stage. 
The survival, at 5 years, of study and control groups 
presenting with LSD, was similar (40% vs 35%). For ESD, 
it was surprising to find that, although not significant 
(logrank; p=0.07), patients in the pregnant group tended 
to have a better survival at 5 years (85%) than those in 
the non-pregnant group (56%). An easy explanation for this 
finding cannot be given, but one could speculate on the 
possible protective influence of associated pregnancy on 
the survival of patients presenting with early stage 
cervical carcinoma. 
Most authors found that it was stage which influenced 
survival of patients with cervical cancer rather than 
associated pregnancyl3,14,16,27,30,34,36,39. In their 
large review, Hacker et al found that compared to a , 
control group, pregnant patients with early carcinoma of 
the cervix (Stages IB and II) had a similar 5-year 
survival (75%), whereas in late disease (stages III and 
IV), the pregnant patients had a lesser survival (16% for 
pregnant patients vs 28% for controls) 15. On the other 
hand Nisker and Shubat found that in 49 pregnant patients 
with stage IB disease the 5-year survival was 70% whilst 
in their control group it was 87%, suggesting that 
survival is adversely affected by coexisting pregnancy 20. 
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Thus the evidence for an effect of pregnancy on 
survival is conflicting. 
3 . Survival according to time of diagnosis. 
In many studies, patients diagnosed postpartum have a 
worse survival than those diagnosed antenatally13,15-
17, 22, 30, 39, 40, 56 Furthermore, some are able to show a 
worse prognosis for patients diagnosed later in pregnancy 
when compared to those diagnosed in the first 
trimester8,13,15,16,27. However, these findings are likely 
to be a function of stage distribution as there is often 
an equivalent stage-for-stage survival according to time 
of diagnosis 8 ,1 3-15,17,39. Only one study has been able to 
demonstrate an improved survival for antenatal patients 
after stratifying for stage22. 
The current study confirms that despite a higher 
proportion of advanced disease in the postpartum patients, 
the survival in this group was similar to that of the 
patients in the antepartum group ( Figure 6) . Moreover, 
multivariate analysis confirms that if stratified for 
stage and method of delivery, patients in the postpartum 
group had a better survival than patients in the antenatal 
group (P<0.03). This finding is graphically illustrated in 
Figure 7. 
One can only speculate upon the explanations for this 
finding. Firstly, this might just be a chance finding. 
However, it may relate to problems, during pregnancy 
itself, with radiation dosimetry, and the need to 
interrupt radiotherapy more frequently because of genital 
tract sepsis15 . Understaging during pregnancy (due to 
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laxity of pelvic ligaments) may possibly give rise to an 
apparent worsening of stage-for-stage survival. 
4. Survival according to method of delivery. 
Vaginal delivery in this study did not adversely 
affect overall or stage-for-stage survival. Other reports 
have reached the same 
after abdominal 
conclusions by comparing 
with that after 
survival 
vaginal 
delivery2, 11, 14, 20, 26, 39. Two studies have even managed 
to show improved survival after vaginal deliveryll, 39. 
Where objections have been raised to delivery through a 
malignant cervix, they are often unsubstantiated, based on 
anecdotal and non-comparative evidence, and refer to 
possible sepsis, dystocia, haemorrhage and dissemination 
of tumour cells during vaginal 
delivery4,10,16,23,24,34,38,40,41,59,60. 
Shingleton and Orr in their review observed that the 
risk of widespread dissemination of carcinoma during 
vaginal delivery may be based more on theoretical 
consideration than on factual findings 2 . The difficulty in 
compiling concise guidelines regarding route of delivery 
is exemplified in the review by Hacker et al. These 
authors found an improved survival of the "vaginal" 
patients but refrained from any further analysis as their 
review was retrospective and involved a number of 
different studiesl5. 
Against this background of uncertainty the results of 
multivariate analysis in the current study are noteworthy. 
Although the influence of vaginal delivery on survival 
does not reach levels of significance, it does show a 
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possible trend (P=0.08). The small numbers involved may 
obscure a more meaningful result. 
Based on both previous reports and findings in the 
current study it is prudent to electively deliver pregnant 
patients with cervical carcinoma, via the abdominal route. 
However, inadvertent vaginal delivery through an untreated 
malignant cervix does not signify decreased survival and 





1) The proportional occurrence of pregnancy-
associated cervical carcinoma is higher at Groote Schuur 
Hospital than elsewhere, but is decreasing with time. 
2) Patients with pregnancy-associated cervical 
carcinoma present with earlier disease and therefore have 
an overall better prognosis than cervical carcinoma 
patients in general. However, survival analysis after 
stratifying for stage, shows that the associated pregnancy 
per se has no influence. 
3) Associated pregnancy does not warrant a deviation 
from an existing treatment protocol for cervical 
carcinoma. 
4) However, in the late second and early third 
trimester intervention may be delayed in the interest of 
fetal maturity without compromising maternal prognosis. 
5) Vaginal delivery in patients with pregnancy-
associated cervical carcinoma, should be avoided. 
6) At GSH, it appears that a postpartum diagnosis has 
a positive effect on prognosis. This does not concur with 
other published studies. 
7) Pregnancy-associated cervical carcinoma at GSH 
seems similar to that described elsewhere, with the 
exception of a worse stage distribution. This difference 
in stage distribution might be a manifestation of "Third 
world" conditions. 
8) The infrequent association of pregnancy with 
cervical carcinoma, precludes unequivocal conclusions. 
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Furthermore, accurate metanalysis is hindered by variable 
reporting. 
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